The Role of Different Molecular Markers in Papillary Thyroid Cancer Patients with Acromegaly

Abstract Purpose Prevalence of papillary thyroid cancer (PTC) is increased in patients with acromegaly. We aimed to determine the protein expression of BRAF, RAS, RET, insulin like growth factor 1(IGF1), Galectine 3, CD56 in patients with PTC related acromegaly and to compare the extensity of these expressions with normal PTC patients and benign thyroid nodules. Methods We studied 313 patients with acromegaly followed in Cerrahpasa Medical Faculty, Endocrinology and Metabolism Clinic between 1998 and 2015. On the basis of availability of pathological specimen of thyroid tissues, thyroid samples of 13 patients from 19 with acromegaly related PTC (APTC), 20 normal PTC and 20 patients with multinodulary goiter (MNG) were histopathologically evaluated. Protein expressions were determined via immunohistochemical staining in ex-vivo tumor samples and benign nodules. Results The incidence of PTC in acromegaly patients were 6% (n=19). Among patients with PTC, APTC and MNG, all the immunohistochemical protein expressions we have studied were higher in papillary thyroid cancer groups (p<0.01, for all). Between PTC group without acromegaly and APTC, galectin 3 and IGF1 expression was significantly higher in acromegalic patients (p<0.01 for all) while RAS was predominantly higher in PTC patients without acromegaly (p<0.01). Conclusion BRAF expression was not higher in PTC with acromegaly patients compared to PTC patients without acromegaly. Galectine 3 and IGF1 were expressed more intensively in APTC. These positive protein expressions may have more influence on determining malign nodules among acromegaly patients.

Download Full-text

LncRNA LUCAT1 as a novel prognostic biomarker for patients with papillary thyroid cancer

Scientific Reports ◽

10.1038/s41598-019-50913-7 ◽

2019 ◽

Vol 9 (1) ◽

Cited By ~ 13

Author(s):

B. Luzón-Toro ◽

R. M. Fernández ◽

J. M. Martos-Martínez ◽

M. Rubio-Manzanares-Dorado ◽

G. Antiñolo ◽

...

Keyword(s):

Cell Cycle ◽

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Ex Vivo ◽

Papillary Thyroid ◽

Extrinsic Pathway ◽

Reverse Transcription Pcr ◽

Enhanced Expression

Abstract In recent years, long non-coding RNAs have emerged as a novel class of regulators of cancer biological processes. While they are dysregulated in many cancer types, little is known about their expression and functional profiles. This study has been focused on the determination of the role of a specific lncRNA in papillary thyroid cancer. Quantitative reverse transcription PCR was performed to detect the expression levels of 84 lncRNAs in 61 papillary thyroid carcinoma tissues and their adjacent non-tumor tissues. The highest fold-change was obtained for lung cancer associated transcript 1 LUCAT1, and thus, this study determines the expression and biological implication of lncRNA LUCAT1 through different in vitro and ex vivo approaches in this tumor. LUCAT1 was specifically located at the cell nucleus in tumoral regions of patient tissues. Furthermore, LUCAT1 knockdown significantly reduced both cell proliferation and invasion ex vivo and induced cell-cycle arrest and apoptosis. These facts were corroborated by an enhanced expression of P21, P57, P53 and BAX, and a reduced expression of EZH2 and HDAC1. In addition, a significant decrease was observed on DNMT1 and NRF2 genes, helping to clarify the role of LUCAT1 on PTC. Our study reveals the involvement of LUCAT1 in PTC development, through acting in cell-cycle regulation, proliferation, epigenetic modifications through LUCAT1/ CDK1/ EZH2/ P57/ P21/ HDAC1/ DNMT1/ P53/ BAX axis and apoptosis, via extrinsic pathway activating caspases. These findings indicate that LUCAT1 is maybe a potential therapeutic target and molecular biomarker for PTC.

Download Full-text

Role of VEGF, CD1a- and CD83 - positive cells in development of papillary thyroid cancer

10.26226/morressier.5b4709886f4cb30010951cd4 ◽

2018 ◽

Author(s):

Koni Ivanova

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Papillary Thyroid

Download Full-text

Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells

Biochemical and Biophysical Research Communications ◽

10.1016/j.bbrc.2008.12.153 ◽

2009 ◽

Vol 379 (2) ◽

pp. 626-631 ◽

Cited By ~ 40

Author(s):

Chi-Iou Lin ◽

Edward E. Whang ◽

Michael A. Abramson ◽

David B. Donner ◽

Monica M. Bertagnolli ◽

...

Keyword(s):

Thyroid Cancer ◽

Cancer Cells ◽

Papillary Thyroid Cancer ◽

Papillary Thyroid ◽

Galectin 3 ◽

Thyroid Cancer Cells

Download Full-text

MON-LB82 Plasma Expression Level of MiRNA -21 Is Related With the Presence of Papillary Thyroid Cancer

Journal of the Endocrine Society ◽

10.1210/jendso/bvaa046.2132 ◽

2020 ◽

Vol 4 (Supplement_1) ◽

Author(s):

Birute Zilaitiene ◽

Aiste Kondrotiene ◽

Daina Pamedytyte ◽

Vaida Simanaviciene ◽

Dalia Dauksiene ◽

...

Keyword(s):

Thyroid Cancer ◽

Healthy Volunteers ◽

Papillary Thyroid Cancer ◽

Diagnostic Value ◽

Healthy Controls ◽

Papillary Thyroid ◽

Expression Levels ◽

Significant Difference ◽

Baseline Levels ◽

Benign Nodules

Abstract Introduction.: There is no effective and reliable biomarker to distinguish benign thyroid nodules (BTN) from papillary thyroid carcinomas (PTC). In this study we analyzed a set of four miRNA molecules in plasma of patients with papillary thyroid cancer, benign nodules and healthy controls to identify miRNA molecules that may be markers of PTC.Aim.: We aimed to investigate the dysregulation of plasma miRNAs in PTC and evaluate the diagnostic value for differentiation of PTC from BTN. Methods.: The expression levels of 4 miRNAs (miR-221, miR-222, miR-146b, miR-21) were measured in 48 PTC patients before thyroidectomy and again after thyroidectomy in a subgroup of 36 patients. Preoperative and postoperative plasma miRNA expression levels were compared with baseline levels established in plasma from the heathy controls group (N=57) and patients with BTN (N=22). MicroRNA-222 and miR-146b, miR-221, miR-21 were included in a panel because they all reportedly were overexpressed in PTC compared to benign nodules or normal thyroid tissue.Results.: Compared with baseline levels in the healthy controls group, miR-221, miR-222, miR-146b, miR-21 levels were significantly higher in the preoperative PTC group (P <0.0001, P=0.002, P=0.028, P =0.021, respectively). A significant reduction in miR-21 expression was observed in postoperative PTC patients. MiR-21 decreased by 5.98-fold (P=0.046) in post- operative samples compared with preoperative samples in the PTC patients.In comparison MiRNRs expression levels in BTN group with healthy controls, miR-221, miR-21 expression levels were significantly higher in the BTN group (P=0.003, P=0.048, respectively). No significant difference was observed between the preoperative PTC group and the preoperative BTN group with regard to the expression of these four miRNA’s. Conclusions: The expression levels of miR-222, miR-146b in plasma were significantly higher in patients who had PTC than in healthy volunteers, whereas levels of miR-221, miR-21 in plasma were significantly higher in patients who had either PTC or BTN before thyroidectomy than in healthy volunteers. Furthermore, miR-21 showed a significant reduction of expression levels after thyroidectomy in PTC patients. However, value of these four miRNAs is still limited in differential diagnosis of PTC and benign nodules.

Download Full-text

A Young Child with Papillary Thyroid Cancer and Metastatic Pulmonary Disease: Role of Radioactive Iodine Therapy in Children

Thyroid Cancer ◽

10.1007/978-3-319-22401-5_27 ◽

2016 ◽

pp. 229-236

Author(s):

Monica L. Arango ◽

Steven G. Waguespack

Keyword(s):

Thyroid Cancer ◽

Young Child ◽

Pulmonary Disease ◽

Papillary Thyroid Cancer ◽

Radioactive Iodine ◽

Radioactive Iodine Therapy ◽

Papillary Thyroid

Download Full-text

The Role of miRNA in Papillary Thyroid Cancer in the Context of miRNA Let-7 Family

International Journal of Molecular Sciences ◽

10.3390/ijms17060909 ◽

2016 ◽

Vol 17 (6) ◽

pp. 909 ◽

Cited By ~ 16

Author(s):

Ewelina Perdas ◽

Robert Stawski ◽

Dariusz Nowak ◽

Maria Zubrzycka

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Papillary Thyroid

Download Full-text

Molecular Imaging of Galectin-1 Expression as a Biomarker of Papillary Thyroid Cancer by Using Peptide-Functionalized Imaging Probes

Biology ◽

10.3390/biology9030053 ◽

2020 ◽

Vol 9 (3) ◽

pp. 53

Author(s):

Deborah Fanfone ◽

Dimitri Stanicki ◽

Denis Nonclercq ◽

Marc Port ◽

Luce Vander Elst ◽

...

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Near Infrared ◽

High Sensitivity ◽

Needle Aspiration ◽

Fluorescence Lifetime Imaging ◽

Papillary Thyroid ◽

Non Invasive ◽

Imaging Probes ◽

Benign Nodules

Thyroid cancers are the most frequent endocrine cancers and their incidence is increasing worldwide. Thyroid nodules occur in over 19–68% of the population, but only 7–15% of them are diagnosed as malignant. Diagnosis relies on a fine needle aspiration biopsy, which is often inconclusive and about 90% of thyroidectomies are performed for benign lesions. Galectin-1 has been proposed as a confident biomarker for the discrimination of malignant from benign nodules. We previously identified by phage display two peptides (P1 and P7) targeting galectin-1, with the goal of developing imaging probes for non-invasive diagnosis of thyroid cancer. The peptides were coupled to ultra-small superparamagnetic particles of iron oxide (USPIO) or to a near-infrared dye (CF770) for non-invasive detection of galectin-1 expression in a mouse model of papillary thyroid cancer (PTC, as the most frequent one) by magnetic resonance imaging and fluorescence lifetime imaging. The imaging probes functionalized with the two peptides presented comparable image enhancement characteristics. However, those coupled to P7 were more favorable, and showed decreased retention by the liver and spleen (known for their galectin-1 expression) and high sensitivity (75%) and specificity (100%) of PTC detection, which confirm the aptitude of this peptide to discriminate human malignant from benign nodules (80% sensitivity, 100% specificity) previously observed by immunohistochemistry.

Download Full-text